To analyse the prognostic impact of plasma MACC1 levels for CRC patients, MACC1 levels were divided into two groups according to the median level (16.91 ng/mL) as MACC1low (<16.91 ng/mL) or MACC1high (>16.91 ng/mL). This evidence concerns the gene MACC1 and colorectal carcinoma.